Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

POLL RESULT OF THE EXTRAORDINARY GENERAL MEETING HELD ON AUGUST 3, 2026

Reference is made to the circular (the "**Circular**") and the notice of the extraordinary general meeting (the "**EGM**") of Sisram Medical Ltd 復銳醫療科技有限公司* (the "**Company**") dated June 24, 2026. Unless otherwise defined in this announcement, terms used herein shall have the same meanings as ascribed to them in the Circular.

At the EGM held on August 3, 2026, the proposed resolution as set out in the notice of the EGM dated June 24, 2026 was taken by poll. The poll result is as follows:

	Ordinary Resolution*	Number of Votes (Approximate % of the total number of votes cast)		
		For	Against	Abstain
1.	THAT: (a) the new supply framework agreement (the "**New Supply Framework Agreement**") entered into between Sisram Medical HK Limited and Fosun Wanbang (Jiangsu) Health Development Co., Ltd* (復星萬邦（江蘇）健康發展有限公司) dated 22 May 2026 and the transactions contemplated thereunder with the relevant proposed annual caps in relation to such transactions be and are hereby approved, confirmed and ratified; and	1,626,440 (99.999877%)	2 (0.000123%)	0 (—)

Ordinary Resolution*		Number of Votes (Approximate % of the total number of votes cast)		
		For	Against	Abstain
	(b) any one director of the Company (a "**Director**") (or where execution under the common seal of the Company is required, any two Directors or any one Director and the company secretary of the Company) be and is/are hereby authorised to do all such further acts and things, negotiate, approve, agree, sign, initial, ratify and/or execute such further documents, instruments and agreements and to take all steps and to do all such acts or things deemed by the Director to be incidental to, ancillary to or in connection with the matters contemplated in the New Supply Framework Agreement and the transactions contemplated thereunder as the Director may in his absolute discretion consider necessary, desirable or expedient to give effect to the New Supply Framework Agreement and the implementation of all transactions contemplated thereunder and to agree with such variation, amendment or waiver as, in the opinion of the Directors, in the interest of the Company and its shareholders as a whole.			

* *The full text of the resolution is set out in the notice to the EGM.*

Notes:

(a) Under the Israeli Companies Law, shareholders of the Company (the "**Shareholders**") are required to declare to the Company whether they have a personal interest (including whether he/she/it is, or has an interest in connection with, a controlling shareholder) in the resolution numbered 1. Votes which are not accompanied by the personal interest declaration will be ignored and will not be counted.

(b) As a majority of the votes were cast in favour of the resolution numbered 1, such resolution was duly passed as an ordinary resolution.

(c) As at the date of the EGM, the total number of shares of the Company ("**Shares**") in issue was 468,343,092 Shares. There were no repurchased Shares pending cancellation or treasury shares held by the Company (including treasury shares held or deposited with the Central Clearing and Settlement System) as at the date of the EGM.

(d) As disclosed in the Circular, 334,504,800 Shares held by Fosun Pharma Industrial Pte. Ltd. ("**FPI**") were required under the Listing Rules to abstain and had abstained from voting on the resolution numbered 1 at the EGM. Accordingly, the number of Shares entitling the Shareholders to attend and vote on the resolution numbered 1 at the EGM was 133,838,292 Shares.

(e) Save as disclosed above, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries: (i) no other Shareholders were required under the Listing Rules to abstain from voting on the resolution numbered 1; and (ii) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution numbered 1 at the EGM as set out in rule 13.40 of the Listing Rules.

(f) None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on the resolution numbered 1 at the EGM.

(g) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

(h) All Directors attended the EGM in person or by electronic means.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, August 3, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*